Clinical Trial Update: A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating Lirilumab (anti-KIR) with Nivolumab (anti-PD-1) and the combination of Nivolumab plus Ipilimumab (anti-CTLA-4) in advanced solid tu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• lirilumab (lirilumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: CANCER,NOS | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-02-02